Regeneron Pharmaceuticals Inc.
Revenue
$4B
Net Income
$1B
Regeneron Pharmaceuticals Inc.
Revenue
$4B
Net Income
$1B
Regeneron Pharmaceuticals Inc.
CIK: 0000872589
Earnings Analysis
Analyzed 11 of 12 reports
Performance Summary - Q2 2026neutral (59)not_provided
Reality-Based Sentiment Analysisneutral59/100
Based on actual market data, not just management spin. Weighted score: 10% management tone + 40% earnings beat/miss + 30% price action + 20% guidance accuracy.
Financial Performance Trend
Overall Analysis & Outlook
Over the past 5 quarters, Regeneron Pharmaceuticals Inc. has been showing bearish trends with stable guidance. Revenue has grown 27.6% during this period. The latest quarter shows neutral sentiment with neutral tone from management.
Latest Quarter Highlights:
Regeneron reported Q2 2026 revenue of $4,290.7M (+16.7% YoY) and net income of $1,296.9M (-6.8% YoY), with strong collaboration revenue growth (+31.9%) driven by Sanofi partnership profits. However, core product sales growth was mixed—Dupixent (+38%) and Libtayo (+30%) showed strength, while EYLEA declined 21% due to biosimilar pressure and managed care restrictions. The company faces significant regulatory headwinds including patent litigation with Amgen, DOJ investigations on anti-kickback compliance, and emerging Dupixent product liability claims.
Detailed Quarterly Reports
In-depth analysis of each quarter's earnings filing
Q2 2026
10-Q • Filed 7/30/2026
Summary
Regeneron reported Q2 2026 revenue of $4,290.7M (+16.7% YoY) and net income of $1,296.9M (-6.8% YoY), with strong collaboration revenue growth (+31.9%) driven by Sanofi partnership profits. However, core product sales growth was mixed—Dupixent (+38%) and Libtayo (+30%) showed strength, while EYLEA declined 21% due to biosimilar pressure and managed care restrictions. The company faces significant regulatory headwinds including patent litigation with Amgen, DOJ investigations on anti-kickback compliance, and emerging Dupixent product liability claims.
Revenue
$4.29B
Net Income
$1.30B
Guidance
Tone
Capex
$470.8M(+5% YoY)
Partnerships
Key Quotes
"As of June 30, 2026, the 'development balance,' which represented the Company's obligation to reimburse Sanofi for development expenses that were previously funded by Sanofi, was fully repaid and will no longer reduce Sanofi collaboration revenue beginning in the third quarter of 2026."
"Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows: Customer A 45%, Customer B 32%"
"On May 15, 2025, the jury reached a verdict in Regeneron's favor on nine of the ten counts submitted to it and awarded Regeneron $135.6 million in compensatory damages and $271.2 million in punitive damages [in Praluent vs. Amgen litigation]"
Q1 2026
10-Q • Filed 4/29/2026
Summary
Q1 2026 revenues grew 19% YoY to $3.6B driven by Dupixent collaboration profits (+42%) and Libtayo growth (+54%), partially offset by EYLEA decline (-12%) due to increasing biosimilar competition. Net income declined 10% to $727M despite higher revenue due to increased R&D spending and IPR&D expenses. Strong cash generation ($1.1B operating cash flow) but facing significant regulatory headwinds including DOJ investigations, patent litigation with competitors, and emerging product liability claims.
Revenue
$3.61B
Net Income
$727.2M
Guidance
Tone
Capex
$230.6M(+0.6% YoY)
Partnerships
Key Quotes
"EYLEA HD sales of $468.4M grew 53% YoY, while total EYLEA declined 12% YoY to $1.67B driven by biosimilar competition"
"Dupixent collaboration revenue of $1.45B grew 42% YoY reflecting strong global sales momentum across multiple indications"
"R&D expenses increased to $1.54B (+16% YoY) reflecting continued investment in pipeline development and acquired IPR&D of $101.9M"
Q4 2025
10-K • Filed 2/4/2026
Summary
Regeneron faces significant headwinds with EYLEA experiencing a 42% decline in US net product sales due to biosimilar competition and compounded bevacizumab pricing pressure, though offset partially by Dupixent collaboration revenue representing 41% of total revenues. The company faces intense regulatory and pricing pressures including FDA staffing reductions, multiple Complete Response Letters for key programs, and emerging government price negotiation initiatives. Supply chain remains constrained with manufacturing capacity limitations, high customer concentration (77% from two distributors), and dependence on Sanofi and Bayer collaborations.
Revenue
$3.88B
Net Income
$844.6M
Guidance
Tone
Partnerships
Key Quotes
"For the year ended December 31, 2025, EYLEA U.S. net product sales declined by 42% compared to the corresponding period in 2024 as a result of competitive pressures and other factors"
"For the years ended December 31, 2025 and 2024, our product sales to two distributor customers accounted on a combined basis for 77% and 74% of our total gross product revenue, respectively"
"Efforts implemented or commenced in 2025 to reduce the size and budgets of U.S. government agencies, downsize the federal workforce, and restructure parts of the executive branch of the federal government have directly or indirectly impacted agencies that support research and development activities or are otherwise important to our business, including the HHS and the FDA"
Q3 2025
10-Q • Filed 10/28/2025
Summary
Regeneron reported Q3 2025 revenues of $3.75 billion and net income of $1.46 billion, with collaboration revenue rising 18.6% YoY to $1.97 billion, driven by the Sanofi partnership. However, net product sales declined 18.4% to $1.59 billion, primarily due to EYLEA erosion from biosimilar competition, partially offset by strong EYLEA HD growth. The company faces significant legal headwinds from patent litigation defending EYLEA against multiple biosimilar competitors and DOJ False Claims Act investigations, while maintaining strong cash generation and continued R&D investment.
Revenue
$3.75B
Net Income
$1.46B
Guidance
Tone
Capex
$649.7M(+16.8% YoY)
Partnerships
Key Quotes
"Net product sales declined 18.4% YoY driven by EYLEA revenue decline from biosimilar competitive pressures"
"Collaboration revenue from Sanofi partnership generated $1.46 billion representing 39% of total revenue"
"Operating cash flow of $3.81 billion for nine months ended September 30, 2025 reflects strong cash generation despite litigation costs"
Q2 2025
10-Q • Filed 8/1/2025
Summary
Regeneron reported Q2 2025 revenue of $3.7 billion and net income of $1.4 billion, with strong collaboration revenue from Sanofi and Bayer partnerships offsetting a 15% decline in net product sales driven by EYLEA erosion due to ongoing biosimilar competition. The company generated robust operating cash flow of $2.2 billion while significantly increasing capex spending by 43% year-over-year, signaling continued investment in manufacturing capacity and pipeline development.
Revenue
$3.68B
Net Income
$1.39B
Guidance
Tone
Capex
$448.3M(+42.6% YoY)
Partnerships
Key Quotes
"Total EYLEA HD and EYLEA U.S. product sales declined from $1,534.7 million in Q2 2024 to $1,147.5 million in Q2 2025, reflecting biosimilar competitive pressures"
"Collaboration revenue increased to $1,860.7 million in Q2 2025 from $1,524.0 million in Q2 2024, driven by Sanofi and Bayer partnerships"
"Capital expenditures increased to $448.3 million for the six months ended June 30, 2025 compared to $314.4 million in the prior year period"
Q1 2025
10-Q • Filed 4/29/2025
Summary
Regeneron reported Q1 2025 revenues of $3,028.7M (down 3.7% YoY) and net income of $808.7M (up 12% YoY), driven by strong collaboration revenue growth (+20.8% YoY to $1,531.2M) primarily from Sanofi partnership, partially offset by a 19.6% decline in net product sales due to EYLEA erosion from biosimilar competitive pressure. The company faces significant headwinds from multiple biosimilar patent litigations and DOJ investigations regarding anti-kickback practices, though recent court victories have affirmed preliminary injunctions against several competitors and a settlement with Mylan/Biocon restricts launch to H2 2026. Strong cash generation ($1,045.1M operating cash flow) and elevated capex spending ($229.3M, +71% YoY) suggest continued investment in manufacturing capacity.
Revenue
$3.03B
Net Income
$808.7M
Guidance
Tone
Capex
$229.3M(+71.3% YoY)
Partnerships
Key Quotes
"On April 14, 2025, the parties entered into a settlement agreement, pursuant to which Mylan and Biocon's appeal to the Federal Circuit and all related litigation have been dismissed and Biocon will be precluded from launching its aflibercept 2 mg biosimilar until the second half of 2026."
"Regeneron's share of profits [from Sanofi collaboration]: Collaboration revenue $1,018.2M (Q1 2025 vs $804.0M Q1 2024)"
"EYLEA HD and EYLEA total sales declined 16% to $1,900.6M in Q1 2025 from $2,251.0M in Q1 2024, with US EYLEA declining 39% YoY due to competitive pressure from biosimilars and market access challenges"
Q4 2024
10-K • Filed 2/5/2025
Summary
Regeneron reported FY 2024 revenues of $14,033 million and net income of $2,213 million, with significant headwinds from EYLEA biosimilar competition following the May 2024 loss of U.S. regulatory exclusivity. EYLEA U.S. sales declined 17% YoY, though partially offset by EYLEA HD (20% of combined U.S. EYLEA/EYLEA HD sales). The company faces substantial regulatory, competitive, and operational challenges, including reliance on two major collaborators (Sanofi and Bayer) for 74% of net product revenue, heightened pricing pressures from government programs, and significant manufacturing capacity constraints.
Revenue
$3.79B
Net Income
$917.7M
Guidance
Tone
Partnerships
Key Quotes
"For the year ended December 31, 2024, EYLEA U.S. net product sales declined by 17% compared to the same period in 2023. Following the expiration of the U.S. regulatory exclusivity period for EYLEA (i.e., the period during which no biosimilar product can be approved by the FDA) in May 2024, several biosimilar versions of EYLEA have been approved by the FDA, and one such product has launched in the United States."
"For the years ended December 31, 2024 and 2023, our product sales to two distributor customers accounted on a combined basis for 74% and 76% of our total gross product revenue, respectively."
"We are substantially dependent on our share of profits from the commercialization of Dupixent under our Antibody Collaboration with Sanofi. For the years ended December 31, 2024 and 2023, Sanofi collaboration revenue (most of which is attributable to our share of profits from the commercialization of Dupixent) represented 32% and 29% of our total revenues, respectively."
Q3 2024
10-Q • Filed 10/31/2024
Summary
Regeneron delivered Q3 2024 revenue of $3.72 billion (up 10.6% YoY) with net income of $1.34 billion, driven by strong product sales growth in EYLEA HD (+818% YoY) and collaboration revenue increases from Sanofi and Bayer. However, the company faces significant regulatory headwinds including multiple biosimilar patent challenges for EYLEA, DOJ investigations related to kickback allegations, and various payors' lawsuits, which create material uncertainty despite solid financial performance and cash generation.
Revenue
$3.72B
Net Income
$1.34B
Guidance
Tone
Capex
$556.3M(+19.1% YoY)
Partnerships
Key Quotes
"Net income per share - diluted $ 11.54 (Q3 2024) vs $ 8.89 (Q3 2023)"
"EYLEA HD U.S. $ 392.3 million (Q3 2024) vs $ 42.7 million (Q3 2023) - representing significant launch success"
"Regeneron's share of profits from Sanofi collaboration $ 1,088.3 million (Q3 2024) vs $ 863.0 million (Q3 2023)"
Q2 2024
10-Q • Filed 8/1/2024
Summary
Regeneron reported Q2 2024 revenue of $3,547.1M (up 12.3% YoY) and net income of $1,432.3M (up 47.9% YoY), driven by strong product sales growth in EYLEA and Libtayo and collaboration revenues from Sanofi and Bayer. The company generated solid operating cash flow of $1,866.5M for the six-month period, with free cash flow of $1,552.1M. However, the company faces significant regulatory headwinds including extensive patent litigation on EYLEA biosimilars across multiple jurisdictions and ongoing DOJ investigations related to anti-kickback and false claims allegations, which could impact future commercialization and profitability.
Revenue
$3.55B
Net Income
$1.43B
Guidance
Tone
Capex
$314.4M(+8% YoY)
Partnerships
Key Quotes
"Three Months Ended June 30, 2024: Net product sales $1,918.6M, Collaboration revenue $1,524.0M, showing strong commercial momentum across key franchises"
"EYLEA products (HD and U.S.) generated $1,534.7M in Q2 2024 compared to $1,500.1M in Q2 2023, with EYLEA HD contributing significantly following launch"
"Libtayo global sales grew to $297.4M in Q2 2024 from $210.0M in Q2 2023, representing 41.6% growth driven by U.S. and international expansion"
Q1 2024
10-Q • Filed 5/2/2024
Summary
Regeneron reported Q1 2024 revenues of $3,145.0 million (down slightly from $3,162.1M in Q1 2023) with net income of $722.0 million, maintaining profitability despite collaboration revenue decline. The company generated strong operating cash flow of $1,512.5 million and free cash flow of $1,378.6 million, though EYLEA U.S. product sales declined 16% YoY while newer products like Libtayo showed strong growth (49% YoY increase). Significant regulatory and litigation headwinds persist, including extensive patent disputes over EYLEA and investigations into compliance practices.
Revenue
$3.15B
Net Income
$722M
Guidance
Tone
Capex
$133.9M(-24.8% YoY)
Partnerships
Key Quotes
"For the three months ended March 31, 2024, the Company's effective tax rate was (3.0%) and 4.7% for the three months ended March 31, 2023, respectively."
"Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows: Besse Medical 51% and McKesson Corporation 24%."
"As of March 31, 2024, the Company's contingent reimbursement obligation to Sanofi under the collaboration was approximately $2.200 billion."
Q3 2023
10-Q • Filed 11/2/2023
Summary
Regeneron reported Q3 2023 net product sales of $1,786.1M (down 0.9% YoY) with collaboration revenue of $1,438.3M (up 36.9% YoY), resulting in total revenues of $3,362.7M and net income of $1,007.8M (down 23.4% YoY). The company faces significant patent litigation exposure, particularly with Amgen over Praluent and multiple biosimilar challenges to EYLEA, while also navigating DOJ investigations related to patient assistance programs and pricing practices. Strong cash generation ($3.5B operating cash flow YTD) and strategic partnerships with Sanofi, Bayer, and others support growth, though top customer concentration (77% from Besse Medical and McKesson) presents risk.
Revenue
$3.36B
Net Income
$1.01B
Guidance
Tone
Capex
$467.2M(+6.7% YoY)
Partnerships
Key Quotes
"During the three months ended September 30, 2023, the Company earned the final $50.0 million sales-based milestone from Sanofi, upon aggregate annual sales of antibodies outside the United States exceeding $3.0 billion on a rolling twelve-month basis."
"Effective July 1, 2022, the Company obtained the exclusive right to develop, commercialize, and manufacture Libtayo worldwide under an Amended and Restated Immuno-oncology License and Collaboration Agreement with Sanofi."
"In September 2023, the Company completed its acquisition of Decibel for hearing loss therapies with up to $97 million in contingent value rights upon achievement of clinical and regulatory milestones."
Sector Comparison
How REGN performs vs Healthcare sector and Biotech peers
Sector Ranking (Healthcare)
Category Ranking (Biotech)
Key Metrics vs Averages
REGN
$4,290.7M
Biotech Avg
$2,626.4M
Healthcare Avg
$2,626.4M
REGN
5.0%
Biotech Avg
27.1%
Healthcare Avg
27.1%
Guidance: not_provided • Tone: neutral